Vesugen: The Vascular Peptide and the Organ Everyone Forgets
A four-amino-acid sequence aimed at blood vessels — a tissue rarely thought of as an organ at all, despite being one of the largest in the body and among the first to show its age.
What Is Vesugen?
Vesugen is a synthesised tetrapeptide — Ala-Glu-Asp-Leu, or AEDL — from the Khavinson programme, directed at the vascular system: the endothelium, meaning the single-cell lining running through every blood vessel in the body.
It is worth pausing on how much tissue that is. The endothelium is often described as one of the body’s largest organs — laid flat it would cover several hundred square metres — yet almost nobody thinks of blood vessels as an organ. They are treated as plumbing. In fact the vessel lining is metabolically active tissue that regulates blood pressure, controls what passes between blood and tissue, and manages inflammation and clotting.
The endothelium, in plain language: imagine the inside of every pipe in a building being lined with sensors and valves rather than being smooth dead metal. The lining constantly measures pressure and flow and adjusts the pipe’s width in response, decides what is allowed to pass through the wall, and repairs small damage as it happens. When that lining stiffens and stops responding, the problem is not the plumbing — it is that the sensors have stopped reading the room. Endothelial ageing is a major research interest for exactly that reason.
What the Research Examines
Published work on Vesugen concerns endothelial function and gene expression in vascular tissue. Studies from the originating institute examine markers of endothelial health, cell proliferation in vascular cultures, and the expression of genes associated with vessel-wall maintenance.
It also appears in combination research, since vascular health underlies almost every other tissue — an organ can only be as healthy as its blood supply. That is why Vesugen shows up alongside other bioregulators in the longevity-focused literature rather than being studied purely in isolation.
The Evidence, Honestly
The same caution applies here as across the synthesised bioregulators, and arguably more so.
The published record is small, preclinical, and originates overwhelmingly from the St. Petersburg institute. There is no independent Western replication of substance and no regulatory approval in any jurisdiction. Cardiovascular research is also a field with unusually high evidence standards — large outcome trials are the norm — which makes the gap between this literature and the surrounding field especially wide.
The mechanism is coherent and the tissue target is a genuinely important one. Neither of those facts is the same as demonstrated effect, and it would be misleading to present the compound as more established than it is.
Frequently Asked Questions
Compiled by the Southern Pacific Labs research team. Last updated July 2026.
Published References
- Khavinson VK, Malinin VV. “Gerontological Aspects of Genome Peptide Regulation.” Karger AG, Basel, 2005. Source
- Anisimov VN, Khavinson VKh. “Peptide bioregulation of aging: results and prospects.” Biogerontology, 2010. PubMed
- Khavinson VKh. “Peptides and Ageing.” Neuro endocrinology letters, 2002. PubMed
- Fedoreyeva LI, Kireev II, Khavinson VKh, et al. “Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA.” Biochemistry. Biokhimiia, 2011. PubMed
Related Research Guides
More in Bioregulators & Neuropeptides
The whole Khavinson system — one peptide per organ, and the honest state of the evidence.
Read guide →Liver BioregulatorA close structural relative aimed at liver tissue, with the chromatin research behind it.
Read guide →Copper PeptideA far better-evidenced peptide also studied in tissue remodelling and vascular contexts.
Read guide →